Immunotherapy for AML & ALL
Immunotherapy was a key topic at iwAL 2018, prompting interesting debates among delegates. Presenters Farhad Ravandi, MD, Roland Walter, MD, PhD, Daniel DeAngelo, MD, PhD, Naval Daver, MD, Noelle Frey, MD, and John DiPersio, MD, PhD, covered a range of subjects in this area, including antibody therapies, checkpoint inhibitors and CAR T-cell therapy.
Presentations
University of Texas MD Anderson Cancer Center, Houston, TX
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about developments in antibody treatments for AML.
Fred Hutchinson Cancer Research Center, Seattle, WA
Roland Walter, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses gemtuzumab ozogamicin.
Dana-Farber Cancer Institute, Boston, MA
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents a talk on targeting CD22+ ALL.
University of Texas MD Anderson Cancer Center, Houston, TX
Naval Daver, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, outlines immune checkpoint inhibitors in AML and MDS.
University of Pennsylvania, Philadelphia, PA
Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, gives a talk on CAR T-cell therapy in B-cell ALL.
Washington University School of Medicine, Washington, WA
John DiPersio, MD, PhD, from Washington University School of Medicine, Washington, WA gives an overview of targeting T-cell malignancies with CAR T-cell therapy.
